The acquisition is a significant step towards realising Paragraf’s ambition of using graphene and other 2D materials to create faster and more-efficient semiconductor devices and technologies.
It will enable Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.
“The world-leading IP and expertise in graphene-electronic-based molecular detection using CRISPR and other bioassay methods from Cardea Bio, combined with Paragraf’s ground-breaking developments in scalable graphene production processes will deliver a strong pipeline of biosensing products aimed at solving major global challenges,” said Simon Thomas, Paragraf CEO and co-founder. “These products will strengthen surveillance of the quality and integrity of our food production processes, markedly improve early detection of disease and monitor the health of our environment. With our existing product lines of current, position and cryogenic sensors – all built on graphene – they will advance Paragraf’s vision of Healthy People, Healthy Cities and Healthy Planet.”
According to Paragraf, the group is now well positioned for strong growth and will continue to support its current partners and commercial commitments while the integration of the new business goes forward, leading to what it describes as a cross-pollination of two world-class IP portfolios, and technology platforms.
By early summer, the company said that it expected the integration to have been completed and the product roadmap enhanced and go-to-market capabilities sped up to the benefit of existing and new customers and partners.
“Joining Paragraf allows us to use the world’s only mass-produced, transfer-free monolayer graphene to manufacture the state-of-the art graphene-based biosensors developed by the Cardea team over the last ten years. We are looking forward to unlocking powerful synergistic effects to advance the broad and growing use of graphene biosensors for the benefit of both people and the planet” said Michael Heltzen, EVP of Strategy at Paragraf USA (former CEO and co-founder of Cardea Bio).
